Concourse Financial Group Securities, Inc. Eliem Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.56 Billion
- Q2 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ELYM
# of Institutions
46Shares Held
49.9MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$251 Million3.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.9MShares$31.2 Million0.91% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.26MShares$26 Million11.93% of portfolio
-
Janus Henderson Group PLC London, X03.25MShares$26 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$20.8 Million1.03% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $212M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...